For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

Imlunestrant worked particularly well in combination with the targeted therapy drug Verzenio. The combo helped women with ...

Surveys suggest that users perceive Mounjaro to be more effective in weight loss, and online pharmacies have seen a shift to ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Novo Nordisk’s (NVO) semaglutide is a GLP-1 weight loss drug marketed as three separate brand name medications, Ozempic, Wegovy, and Rybelsus. Novo’s Wegovy competes with Eli Lilly’s (LLY) Zepbound.

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Robert F. Kennedy Jr., a prominent critic of the pharmaceutical industry, discussed his views regarding GLP-1 weight loss drugs in a televised broadcast.

Jeffrey Segal MD, JD, a medico-legal expert and the founder of Medical Justice, discussed the shifting dynamics of the market for GLP-1 receptor agonist medications in a recent blog, “The Whirlwind ...

Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound. Through Ro's platform, eligible patients can receive ...